Sanara Medtech Inc. develops and commercializes technologies to improve clinical outcomes and reduce healthcare costs in surgical, chronic wound, and skincare markets. It offers products like CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus, BIASURGE, FORTIFY TRG Tissue Repair Graft, and FORTIFY FLOWABLE Extracellular Matrix for various surgical specialties. These products help promote healing and reduce complications in cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and more. The company also has multiple products in its pipeline. The SMTI stock yearly return is shown above.
The yearly return on the SMTI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2025 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SMTI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|